OncoRx Insights accelerates access to the most
effective and precise cancer treatments.
See how the bold vision of OncoRx Insights is revolutionizing how oncologists work.
How It Works Our Mission
Utilizing AI technology to bridge relationships between the oncologist, pharmaceutical companies, and patients, giving cancer patients access to rapidly emerging treatments.
Deliver Actionable Insights to Patients, Oncologists, Health Plans and Pharmaceutical Companies
Molecular Diagnostics Reports
Enable Cost Efficiency for Health Plans
Outcomes Detected,
Matched to Treatment
ONCOLOGISTS
PHARMA
HEALTH PLANS
Integrity is at the heart of everything we do – from system design, to providing valuable insights and recommendations, to securing your data.
Our processes are all designed with the same thought in mind: making it easier for oncologists to care for patients.
OncoRx Insights has been selected to join @Larta Institute’s Heal LA Program. We’re thrilled to be counted among the 2026 cohort of 30 diverse startups that are leveraging innovation to improve the health and wellness of at-risk communities in Los Angeles.
We would like to extend our gratitude to Larta, program sponsors, the steering committee, and our supporters for granting us this incredible opportunity. We look forward to collaborating with you all to foster better health and wellness outcomes in our communities.
Kristin Ashcraft, Co-Founder and CEO of OncoRx Insights, is determined to bring current information to community-based oncologists to help them identify precision therapies for their patients.
Community oncologists care for most cancer patients in the United States, yet often lack the time, support, and infrastructure needed to fully implement precision medicine. In this episode of the Exploring AI in Oncology series, Waqas Haque, MD, MPH, speaks with Kristin Ashcraft, CEO and Co-Founder of OncoRx Insights, about how an AI-driven digital health platform can help close the precision medicine access gap in community settings.
In light of the recent understanding of the molecular complexity of cancer and the costs of corresponding targeted treatments such as immunotherapies and CAR-T, there are legitimate questions that arise regarding precision oncology. Are community cancer patients getting the best possible care? Are pharmaceutical companies optimising the market potential for these expensive therapies?
Orilio didn’t know how long she had to live after her stage-four lung cancer diagnosis. The disease had already infiltrated her eye, so the 31-year-old didn’t bother opening a retirement account.
PJ DiPentino felt uneasy about his local oncologist’s plan. DiPentino’s bladder cancer had returned in a lymph node, and the doctor was recommending he continue immunotherapy and wait to see if it spread.
Personalized medicine presents new opportunities for patients with cancer. However, many patients do not receive the most effective personalized treatments because of challenges associated with integrating predictive biomarker testing into clinical care.
The OncoRx Insights platform enables “one stop shopping” by presenting molecular diagnostic reports from different labs in a common, easily understood format, and integrates the reports and real-time research in one place. The product helps oncologists be more efficient with our time and treatment recommendations. Also, we can use the platform to securely communicate with colleagues regarding NGS reports.
Next generation sequencing reports are long, dense, and complicated. OncoRx Insights translates key findings into easily consumed visuals. This simplifies decisions on potential treatments, indications, side effects and dose modifications. The result? Improved, evidence-based care – and time saved.
The Holy Grail in my world has been understanding the patient journey so that we can solve for whatever issues patients are having along the way. There’s a lot of value there.
